ORGO vs DBVT

Organogenesis Holdings Inc.

(ORGO) offers the better valuation at 17. 1x trailing P/E, making it the more compelling value choice. Analysts rate Organogenesis Holdings Inc. (ORGO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, DBV Technologies S.

A. (DBVT) delivered a total return of -66. 6%, compared to -87. 6% for Organogenesis Holdings Inc. (ORGO). Over 10 years, the gap is even starker: ORGO returned -73. 7% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Organogenesis Holdings Inc. 's 1. 92β — meaning ORGO is approximately 53% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 27% for Organogenesis Holdings Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Organogenesis Holdings Inc.

grew EPS 1600% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Organogenesis Holdings Inc.

(ORGO) is the more profitable company, earning 10. 1% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 10. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ORGO leads at 7. 9% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ORGO leads at 44. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ORGO (3.

4% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, DBV Technologies S.

A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Organogenesis Holdings Inc. (ORGO) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -86. 8%, ORGO: -73. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ORGO is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. ORGO pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.